A Novel Analgesia Technique for ACL Reconstruction
NCT03292926 is a phase 4 interventional trial sponsored by Hospital for Special Surgery, New York. As of 18 Nov 2026, it is completed. It studies Bupivacaine and Dexamethasone in Anterior Cruciate Ligament Injury. The registry lists an enrollment of 78 participants at 1 site in 1 country. The registry lists a start date of 4 Oct 2017 and a primary completion date of 6 Mar 2020.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03292926 |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional trial |
| Lead sponsor | Hospital for Special Surgery, New York |
| Enrollment | 78 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Anterior Cruciate Ligament Injury |
| Drugs | Bupivacaine and Dexamethasone |
| Start | 4 Oct 2017 |
| Primary completion | 6 Mar 2020 |
| Study completion | 16 Apr 2020 |
| Last update posted | 19 Sept 2024 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Jonathan Beathe, MD
Hospital for Special Surgery, New York
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hospital for Special Surgery
New York
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03292926
Each answer restates registry values shown on this page.
What is NCT03292926?
NCT03292926 is a phase 4 interventional trial sponsored by Hospital for Special Surgery, New York. It studies Bupivacaine and Dexamethasone in Anterior Cruciate Ligament Injury.
Who leads NCT03292926?
The registry names Jonathan Beathe, MD (principal investigator, Hospital for Special Surgery, New York) as the overall official.
Where does NCT03292926 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT03292926 study?
The registered drug and biological interventions are Bupivacaine and Dexamethasone.
When did NCT03292926 end?
The registry lists a primary completion date of 6 Mar 2020 and a study completion date of 16 Apr 2020. The sponsor last updated the record on 19 Sept 2024.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.